₪
13.11
Apr 25
Business Description
Rekah Pharmaceutical Prod Ltd
ISIN : IL0010810096
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.11 | |||||
Equity-to-Asset | 0.32 | |||||
Debt-to-Equity | 1.18 | |||||
Debt-to-EBITDA | 5.89 | |||||
Interest Coverage | 0.65 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.25 | |||||
Beneish M-Score | -2.54 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.6 | |||||
3-Year EBITDA Growth Rate | -7.7 | |||||
3-Year Book Growth Rate | -2.1 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.09 | |||||
9-Day RSI | 40.23 | |||||
14-Day RSI | 41.68 | |||||
6-1 Month Momentum % | -16.45 | |||||
12-1 Month Momentum % | -14.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.75 | |||||
Quick Ratio | 1.08 | |||||
Cash Ratio | 0.13 | |||||
Days Inventory | 141.08 | |||||
Days Sales Outstanding | 138.59 | |||||
Days Payable | 131.68 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -7.49 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 24.93 | |||||
Operating Margin % | 1.67 | |||||
Net Margin % | -2.15 | |||||
FCF Margin % | 5.14 | |||||
ROE % | -4.33 | |||||
ROA % | -1.47 | |||||
ROIC % | 1.5 | |||||
ROC (Joel Greenblatt) % | 0.47 | |||||
ROCE % | 0.38 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 14.19 | |||||
PS Ratio | 0.45 | |||||
PB Ratio | 0.94 | |||||
Price-to-Tangible-Book | 1.69 | |||||
Price-to-Free-Cash-Flow | 8.33 | |||||
Price-to-Operating-Cash-Flow | 4.98 | |||||
EV-to-EBIT | 252.58 | |||||
EV-to-EBITDA | 10.07 | |||||
EV-to-Revenue | 0.98 | |||||
EV-to-FCF | 18.77 | |||||
Price-to-Projected-FCF | 0.74 | |||||
Earnings Yield (Greenblatt) % | 0.4 | |||||
FCF Yield % | 11.05 | |||||
Forward Rate of Return (Yacktman) % | 13.1 |